Granules India gets US FDA nod for Potassium Chloride Oral Solution

Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis
Read Article

Granules India announced that the US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, a wholly-owned foreign subsidiary of Granules India, for Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%). It is bioequivalent to the reference listed drug product (RLD), Potassium Chloride Oral Solution, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%), of Genus Lifesciences. The product would be available in a bottle of 473 ml and is expected to be launched shortly.

“We are pleased to announce approval of first oral liquid product from our growing product portfolio in the US market. This is third approval in the Potassium Chloride product basket reiterating our focused portfolio strategy.” said Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals, commenting on the approval.

Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.

Granules now has a total of 36 ANDA approvals from US FDA (35 Final approvals and one tentative approvals). Potassium Chloride Oral solution products had US sales of approximately $75 million for the most recent twelve months ending in November 2020 according to IQVIA Health.

ANDA approvalGranules IndiahypokalemiaPotassium ChloridePotassium Chloride Oral SolutionUS FDA
Comments (0)
Add Comment